Researchers highlight role of tryptase genotyping in diagnosing mastocytosis
Tryptase genotyping helps determine whether a high tryptase level reflects disease or genetics in systemic mastocytosis (SM).
Tryptase genotyping helps determine whether a high tryptase level reflects disease or genetics in systemic mastocytosis (SM).
Patients with systemic mastocytosis (SM) face significantly increased risks of melanoma and other skin cancers.
HT-KIT cut KIT protein levels by more than 80% and halted tumor growth in systemic mastocytosis (SM) models.
A patient with systemic mastocytosis suffered a life-threatening immune reaction after receiving an mRNA-1273 COVID-19 booster.
Results from a recent study could support more accurate diagnosis and future therapies in indolent systemic mastocytosis.
A clinical trial is testing avapritinib and decitabine to improve outcomes for patients with SM and an associated blood cancer.
The HARBOR study will compare elenestinib with a placebo and best supportive care to determine its effectiveness in treating ISM.
AI models analyzed electronic health records to predict which patients may have undiagnosed systemic mastocytosis.
The study highlights the risks of relying on social media for medical advice.
A recent case study describes how mast cell leukemia can present unusual symptoms that complicate diagnosis.